Experimental cutaneous leishmaniasis: transmission electron microscopy of the inoculation site
Tissue response against inoculation of Leishmania (Leishmania) amazonensis promastigotes in the hind footpad was quite different between two strains of mice: in BALB/c animals there was parasitism of perineurial cells by the 8th week post inoculation (WPI) and heavy parasitism of macrophages, as well as degenerated extracellular parasites close to ...
C, Vasconcellos, M N, Sotto
openaire +3 more sources
BackgroundCurrent therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and the development of resistance.
Cesar Miranda-Verastegui +8 more
doaj +1 more source
Leishmania tarentolae as Potential Live Vaccine Co-Expressing Distinct Salivary Gland Proteins Against Experimental Cutaneous Leishmaniasis in BALB/c Mice Model. [PDF]
Lajevardi MS +7 more
europepmc +1 more source
Studies on the infectivity and pathogenecity of Leishmania species from Leishmaniasis diffusa and on the immune response of the host in laboratory animals [PDF]
1. The infectivity of three strains of Leishmania braziliensis pifanoi, strain V1 and V2 from Venezuela and L 15 from Brazil was studied in albino, hairless, "shaven" and "shaven" x albino mice; in hamsters, rats and guinea pigs. Rats and guinea-pigs
Hayatee, Zuhair
core +1 more source
Evaluation of PCR as a diagnostic mass-screening tool to detect Leishmania (Viannia) spp. in domestic dogs (Canis familiaris) [PDF]
Several studies have suggested that the PCR could be used in epidemiological mass-screening surveys to detect Leishmania (Piannia) spp. infection in human and animal hosts.
Reithinger, Richard +7 more
core +1 more source
Leishmaniasis is a complex disease caused by protozoan parasites of the genus Leishmania, which are transmitted by phlebotomine sand flies. The clinical manifestations of leishmaniasis are diverse, ranging from self-healing cutaneous lesions to fatal ...
Mahmoud Nateghi-Rostami +5 more
doaj +1 more source
BackgroundThe only oral drug available for the treatment of leishmaniasis is miltefosine, described and approved for visceral leishmaniasis in India. Miltefosine is under evaluation for the treatment of cutaneous leishmaniasis in the Americas although ...
Juliana Q Reimão +5 more
doaj +1 more source
MPLA and AddaVax® Adjuvants Fail to Promote Intramuscular LaAg Vaccine Protectiveness against Experimental Cutaneous Leishmaniasis. [PDF]
Oliveira-Maciel D +10 more
europepmc +1 more source
Drug-containing hydrophobic dressings as a topical experimental therapy for cutaneous leishmaniasis
Cutaneous leishmaniasis (CL), a clinical condition caused mainly by Leishmania amazonensis in Brazil, is characterized by topical, painless ulcers. The current treatment, based on intravenous administration of pentavalent antimonials, presents low adherence by patients and may cause serious adverse effects, leading to the need for searching new ...
Viviane Pereira +5 more
openaire +3 more sources
Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda [PDF]
BACKGROUND: In East Africa, visceral leishmaniasis (VL) is endemic in parts of Sudan, Ethiopia, Somalia, Kenya and Uganda. It is caused by Leishmania donovani and transmitted by the sandfly vector Phlebotomus martini.
Kolaczinski, Jan H +27 more
core +2 more sources

